Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AMG 317 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AMG 317 75 mg | EXPERIMENTAL | 75 subjects |
| Placebo Arm | PLACEBO_COMPARATOR | 75 subjects |
| AMG 317 300 mg | EXPERIMENTAL | 75 subjects |
| AMG 317 150 mg | EXPERIMENTAL | 75 subjects |
| Name | Type | Description |
|---|---|---|
| AMG 317 75 mg | BIOLOGICAL | 75 mg SC weekly injection |
| AMG 317 150 mg | BIOLOGICAL | 150 mg SC once weekly injection |
| AMG 317 300 mg | BIOLOGICAL | 300 mg weekly SC injection |
| Placebo | BIOLOGICAL | Placebo SC once weekly injection |
Inclusion Criteria: * Males or females 18 to 65 years of age at the time of screening * Baseline percent of predicted FEV1 ≥ 50% to ≤ 80% at screening * At least 12% reversibility over baseline FEV1 with beta agonist inhalation, which can be demonstrated in the office or documented by medical recor...
AMG 317 is an investigational monoclonal antibody being developed for the treatment of asthma. It is intended for use in patients with asthma, as studied in a Phase 2 clinical trial. The drug is not yet approved and remains in clinical development.
AMG 317 is a monoclonal antibody, but its specific molecular target has not been disclosed in the available information. As a monoclonal antibody, it is designed to bind to a specific protein involved in the disease process, but the exact target is not specified.
AMG 317 is being developed by Amgen Inc., a biotechnology company traded on the NASDAQ under the ticker symbol AMGN. Amgen is responsible for the clinical development of this investigational drug for asthma.
AMG 317 is in Phase 2 clinical development. It has completed a Phase 2 trial, and there are no active trials currently listed. The drug is investigational and has not been approved by regulatory authorities.
AMG 317 has been studied in one completed Phase 2 clinical trial, identified as NCT00436670. This trial was a randomized, double-blind, placebo-controlled study that enrolled 294 participants with asthma. The trial has been completed, and no active trials are currently ongoing.